Estimated 2-year PFS2 with 2L BTKi in relapsed/refractory mantle cell lymphoma

Estimate 2-year Mantle Cell Lymphoma PFS2

Questions

1.MIPI risk category at diagnosis?

2.Ki67 at diagnosis?

3.Blastoid/pleomorphic at diagnosis?

4.Time to 2L BTKi (months)?

About

Estimated 2-year PFS2 with 2L BTKi in relapsed/refractory mantle cell lymphoma

References

D. Villa, A. Jiang, N. Crosbie, S. Rule, R. McCulloch et al,

Impact of time to second line Bruton tyrosine kinase therapy in patients with first relapse of mantle cell lymphoma: TIME TO SECOND LINE BRUTON TYROSINE KINASE THERAPY AND AGE AT ITS INITIATION ARE STRONGLY ASSOCIATED WITH SUBSEQUENT OVERALL SURVIVAL IN PATIENTS WITH FIRST RELAPSE OF MANTLE CELL LYMPHOMA

Hematological Oncology: 17 June 2021

The Estimated 2-year PFS2 with 2L BTKi in relapsed/refractory mantle cell lymphoma calculator is created by QxMD.

Default Units

1. MIPI risk category at diagnosis?

0/4 completed

About

Estimated 2-year PFS2 with 2L BTKi in relapsed/refractory mantle cell lymphoma

References

D. Villa, A. Jiang, N. Crosbie, S. Rule, R. McCulloch et al,

Hematological Oncology: 17 June 2021

The Estimated 2-year PFS2 with 2L BTKi in relapsed/refractory mantle cell lymphoma calculator is created by QxMD.

Contributed By:

Aixiang Jiang

Legal Notices and Disclaimer

© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.